RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis..     ///    Molecular inhibitors that block RET/PTC or BRAF kinase activity have shown substantial therapeutic effects in the experimental systems and are currently being tested in clinical trials.. 